1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Pain Management Drugs
1.2.3 Corticosteroids
1.2.4 Prednisolone
1.2.5 Prednisone
1.2.6 Deflazacort
1.3 Market by Application
1.3.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Home Care
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Duchenne Muscular Dystrophy Therapeutics Market Perspective (2017-2028)
2.2 Duchenne Muscular Dystrophy Therapeutics Growth Trends by Region
2.2.1 Duchenne Muscular Dystrophy Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Duchenne Muscular Dystrophy Therapeutics Historic Market Size by Region (2017-2022)
2.2.3 Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Region (2023-2028)
2.3 Duchenne Muscular Dystrophy Therapeutics Market Dynamics
2.3.1 Duchenne Muscular Dystrophy Therapeutics Industry Trends
2.3.2 Duchenne Muscular Dystrophy Therapeutics Market Drivers
2.3.3 Duchenne Muscular Dystrophy Therapeutics Market Challenges
2.3.4 Duchenne Muscular Dystrophy Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Duchenne Muscular Dystrophy Therapeutics Players by Revenue
3.1.1 Global Top Duchenne Muscular Dystrophy Therapeutics Players by Revenue (2017-2022)
3.1.2 Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Players (2017-2022)
3.2 Global Duchenne Muscular Dystrophy Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Duchenne Muscular Dystrophy Therapeutics Revenue
3.4 Global Duchenne Muscular Dystrophy Therapeutics Market Concentration Ratio
3.4.1 Global Duchenne Muscular Dystrophy Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy Therapeutics Revenue in 2021
3.5 Duchenne Muscular Dystrophy Therapeutics Key Players Head office and Area Served
3.6 Key Players Duchenne Muscular Dystrophy Therapeutics Product Solution and Service
3.7 Date of Enter into Duchenne Muscular Dystrophy Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Duchenne Muscular Dystrophy Therapeutics Breakdown Data by Type
4.1 Global Duchenne Muscular Dystrophy Therapeutics Historic Market Size by Type (2017-2022)
4.2 Global Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Type (2023-2028)
5 Duchenne Muscular Dystrophy Therapeutics Breakdown Data by Application
5.1 Global Duchenne Muscular Dystrophy Therapeutics Historic Market Size by Application (2017-2022)
5.2 Global Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Duchenne Muscular Dystrophy Therapeutics Market Size (2017-2028)
6.2 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Type
6.2.1 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2017-2022)
6.2.2 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2023-2028)
6.2.3 North America Duchenne Muscular Dystrophy Therapeutics Market Share by Type (2017-2028)
6.3 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Application
6.3.1 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2017-2022)
6.3.2 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2023-2028)
6.3.3 North America Duchenne Muscular Dystrophy Therapeutics Market Share by Application (2017-2028)
6.4 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Country
6.4.1 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2017-2022)
6.4.2 North America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Duchenne Muscular Dystrophy Therapeutics Market Size (2017-2028)
7.2 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Type
7.2.1 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2017-2022)
7.2.2 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2023-2028)
7.2.3 Europe Duchenne Muscular Dystrophy Therapeutics Market Share by Type (2017-2028)
7.3 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Application
7.3.1 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2017-2022)
7.3.2 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2023-2028)
7.3.3 Europe Duchenne Muscular Dystrophy Therapeutics Market Share by Application (2017-2028)
7.4 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Country
7.4.1 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2017-2022)
7.4.2 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size (2017-2028)
8.2 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Type
8.2.1 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Share by Type (2017-2028)
8.3 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Application
8.3.1 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Share by Application (2017-2028)
8.4 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Region
8.4.1 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size (2017-2028)
9.2 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Type
9.2.1 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2017-2022)
9.2.2 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2023-2028)
9.2.3 Latin America Duchenne Muscular Dystrophy Therapeutics Market Share by Type (2017-2028)
9.3 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Application
9.3.1 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2017-2022)
9.3.2 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2023-2028)
9.3.3 Latin America Duchenne Muscular Dystrophy Therapeutics Market Share by Application (2017-2028)
9.4 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Country
9.4.1 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2017-2022)
9.4.2 Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size (2017-2028)
10.2 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Type
10.2.1 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Share by Type (2017-2028)
10.3 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Application
10.3.1 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Share by Application (2017-2028)
10.4 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Country
10.4.1 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Details
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Introduction
11.1.4 Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022)
11.1.5 Bristol-Myers Squibb Recent Developments
11.2 FibroGen (US)
11.2.1 FibroGen (US) Company Details
11.2.2 FibroGen (US) Business Overview
11.2.3 FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Introduction
11.2.4 FibroGen (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022)
11.2.5 FibroGen (US) Recent Developments
11.3 Italfarmaco (Italy)
11.3.1 Italfarmaco (Italy) Company Details
11.3.2 Italfarmaco (Italy) Business Overview
11.3.3 Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Introduction
11.3.4 Italfarmaco (Italy) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022)
11.3.5 Italfarmaco (Italy) Recent Developments
11.4 Marathon
11.4.1 Marathon Company Details
11.4.2 Marathon Business Overview
11.4.3 Marathon Duchenne Muscular Dystrophy Therapeutics Introduction
11.4.4 Marathon Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022)
11.4.5 Marathon Recent Developments
11.5 NS Pharma (US)
11.5.1 NS Pharma (US) Company Details
11.5.2 NS Pharma (US) Business Overview
11.5.3 NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Introduction
11.5.4 NS Pharma (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022)
11.5.5 NS Pharma (US) Recent Developments
11.6 PTC Therapeutics (US)
11.6.1 PTC Therapeutics (US) Company Details
11.6.2 PTC Therapeutics (US) Business Overview
11.6.3 PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Introduction
11.6.4 PTC Therapeutics (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022)
11.6.5 PTC Therapeutics (US) Recent Developments
11.7 Pfizer
11.7.1 Pfizer Company Details
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Duchenne Muscular Dystrophy Therapeutics Introduction
11.7.4 Pfizer Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022)
11.7.5 Pfizer Recent Developments
11.8 ReveraGen BioPharma (US)
11.8.1 ReveraGen BioPharma (US) Company Details
11.8.2 ReveraGen BioPharma (US) Business Overview
11.8.3 ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Introduction
11.8.4 ReveraGen BioPharma (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022)
11.8.5 ReveraGen BioPharma (US) Recent Developments
11.9 Santhera Pharmaceuticals (Switzerland)
11.9.1 Santhera Pharmaceuticals (Switzerland) Company Details
11.9.2 Santhera Pharmaceuticals (Switzerland) Business Overview
11.9.3 Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Introduction
11.9.4 Santhera Pharmaceuticals (Switzerland) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022)
11.9.5 Santhera Pharmaceuticals (Switzerland) Recent Developments
11.10 Sarepta Therapeutics (US)
11.10.1 Sarepta Therapeutics (US) Company Details
11.10.2 Sarepta Therapeutics (US) Business Overview
11.10.3 Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Introduction
11.10.4 Sarepta Therapeutics (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022)
11.10.5 Sarepta Therapeutics (US) Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Duchenne Muscular Dystrophy Therapeutics Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Pain Management Drugs
Table 3. Key Players of Corticosteroids
Table 4. Key Players of Prednisolone
Table 5. Key Players of Prednisone
Table 6. Key Players of Deflazacort
Table 7. Global Duchenne Muscular Dystrophy Therapeutics Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 8. Global Duchenne Muscular Dystrophy Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 9. Global Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 10. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Region (2017-2022)
Table 11. Global Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 12. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Region (2023-2028)
Table 13. Duchenne Muscular Dystrophy Therapeutics Market Trends
Table 14. Duchenne Muscular Dystrophy Therapeutics Market Drivers
Table 15. Duchenne Muscular Dystrophy Therapeutics Market Challenges
Table 16. Duchenne Muscular Dystrophy Therapeutics Market Restraints
Table 17. Global Duchenne Muscular Dystrophy Therapeutics Revenue by Players (2017-2022) & (US$ Million)
Table 18. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Players (2017-2022)
Table 19. Global Top Duchenne Muscular Dystrophy Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy Therapeutics as of 2021)
Table 20. Ranking of Global Top Duchenne Muscular Dystrophy Therapeutics Companies by Revenue (US$ Million) in 2021
Table 21. Global 5 Largest Players Market Share by Duchenne Muscular Dystrophy Therapeutics Revenue (CR5 and HHI) & (2017-2022)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Duchenne Muscular Dystrophy Therapeutics Product Solution and Service
Table 24. Date of Enter into Duchenne Muscular Dystrophy Therapeutics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 27. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Type (2017-2022)
Table 28. Global Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 29. Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Type (2023-2028)
Table 30. Global Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 31. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Application (2017-2022)
Table 32. Global Duchenne Muscular Dystrophy Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 33. Global Duchenne Muscular Dystrophy Therapeutics Revenue Share by Application (2023-2028)
Table 34. North America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 35. North America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 36. North America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 37. North America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 38. North America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 39. North America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 40. Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 41. Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 42. Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 43. Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 44. Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 45. Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 46. Asia Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 47. Asia Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 48. Asia Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 49. Asia Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 50. Asia Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 51. Asia Pacific Duchenne Muscular Dystrophy Therapeutics Market Size by Region (2023-2028) & (US$ Million)
Table 52. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 53. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 54. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 55. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 56. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 57. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2023-2028) & (US$ Million)
Table 60. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 61. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2023-2028) & (US$ Million)
Table 62. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 63. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 64. Bristol-Myers Squibb Company Details
Table 65. Bristol-Myers Squibb Business Overview
Table 66. Bristol-Myers Squibb Duchenne Muscular Dystrophy Therapeutics Product
Table 67. Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022) & (US$ Million)
Table 68. Bristol-Myers Squibb Recent Developments
Table 69. FibroGen (US) Company Details
Table 70. FibroGen (US) Business Overview
Table 71. FibroGen (US) Duchenne Muscular Dystrophy Therapeutics Product
Table 72. FibroGen (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022) & (US$ Million)
Table 73. FibroGen (US) Recent Developments
Table 74. Italfarmaco (Italy) Company Details
Table 75. Italfarmaco (Italy) Business Overview
Table 76. Italfarmaco (Italy) Duchenne Muscular Dystrophy Therapeutics Product
Table 77. Italfarmaco (Italy) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022) & (US$ Million)
Table 78. Italfarmaco (Italy) Recent Developments
Table 79. Marathon Company Details
Table 80. Marathon Business Overview
Table 81. Marathon Duchenne Muscular Dystrophy Therapeutics Product
Table 82. Marathon Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022) & (US$ Million)
Table 83. Marathon Recent Developments
Table 84. NS Pharma (US) Company Details
Table 85. NS Pharma (US) Business Overview
Table 86. NS Pharma (US) Duchenne Muscular Dystrophy Therapeutics Product
Table 87. NS Pharma (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022) & (US$ Million)
Table 88. NS Pharma (US) Recent Developments
Table 89. PTC Therapeutics (US) Company Details
Table 90. PTC Therapeutics (US) Business Overview
Table 91. PTC Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product
Table 92. PTC Therapeutics (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022) & (US$ Million)
Table 93. PTC Therapeutics (US) Recent Developments
Table 94. Pfizer Company Details
Table 95. Pfizer Business Overview
Table 96. Pfizer Duchenne Muscular Dystrophy Therapeutics Product
Table 97. Pfizer Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022) & (US$ Million)
Table 98. Pfizer Recent Developments
Table 99. ReveraGen BioPharma (US) Company Details
Table 100. ReveraGen BioPharma (US) Business Overview
Table 101. ReveraGen BioPharma (US) Duchenne Muscular Dystrophy Therapeutics Product
Table 102. ReveraGen BioPharma (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022) & (US$ Million)
Table 103. ReveraGen BioPharma (US) Recent Developments
Table 104. Santhera Pharmaceuticals (Switzerland) Company Details
Table 105. Santhera Pharmaceuticals (Switzerland) Business Overview
Table 106. Santhera Pharmaceuticals (Switzerland) Duchenne Muscular Dystrophy Therapeutics Product
Table 107. Santhera Pharmaceuticals (Switzerland) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022) & (US$ Million)
Table 108. Santhera Pharmaceuticals (Switzerland) Recent Developments
Table 109. Sarepta Therapeutics (US) Company Details
Table 110. Sarepta Therapeutics (US) Business Overview
Table 111. Sarepta Therapeutics (US) Duchenne Muscular Dystrophy Therapeutics Product
Table 112. Sarepta Therapeutics (US) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022) & (US$ Million)
Table 113. Sarepta Therapeutics (US) Recent Developments
Table 114. Research Programs/Design for This Report
Table 115. Key Data Information from Secondary Sources
Table 116. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Type: 2021 VS 2028
Figure 2. Pain Management Drugs Features
Figure 3. Corticosteroids Features
Figure 4. Prednisolone Features
Figure 5. Prednisone Features
Figure 6. Deflazacort Features
Figure 7. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Application: 2021 VS 2028
Figure 8. Hospitals Case Studies
Figure 9. Clinics Case Studies
Figure 10. Home Care Case Studies
Figure 11. Duchenne Muscular Dystrophy Therapeutics Report Years Considered
Figure 12. Global Duchenne Muscular Dystrophy Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 13. Global Duchenne Muscular Dystrophy Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Region: 2021 VS 2028
Figure 15. Global Duchenne Muscular Dystrophy Therapeutics Market Share by Players in 2021
Figure 16. Global Top Duchenne Muscular Dystrophy Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Duchenne Muscular Dystrophy Therapeutics as of 2021)
Figure 17. The Top 10 and 5 Players Market Share by Duchenne Muscular Dystrophy Therapeutics Revenue in 2021
Figure 18. North America Duchenne Muscular Dystrophy Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 19. North America Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Type (2017-2028)
Figure 20. North America Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Application (2017-2028)
Figure 21. North America Duchenne Muscular Dystrophy Therapeutics Market Size Share by Country (2017-2028)
Figure 22. United States Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Canada Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Europe Duchenne Muscular Dystrophy Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 25. Europe Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Type (2017-2028)
Figure 26. Europe Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Application (2017-2028)
Figure 27. Europe Duchenne Muscular Dystrophy Therapeutics Market Size Share by Country (2017-2028)
Figure 28. Germany Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. France Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. U.K. Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Italy Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Russia Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Nordic Countries Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Asia-Pacific Duchenne Muscular Dystrophy Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 35. Asia Pacific Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Type (2017-2028)
Figure 36. Asia Pacific Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Application (2017-2028)
Figure 37. Asia Pacific Duchenne Muscular Dystrophy Therapeutics Market Size Share by Region (2017-2028)
Figure 38. China Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Japan Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. South Korea Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Southeast Asia Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. India Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Australia Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 44. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 45. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Type (2017-2028)
Figure 46. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Application (2017-2028)
Figure 47. Latin America Duchenne Muscular Dystrophy Therapeutics Market Size Share by Country (2017-2028)
Figure 48. Mexico Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 49. Brazil Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 50. Middle East & Africa Duchenne Muscular Dystrophy Therapeutics Market Size YoY (2017-2028) & (US$ Million)
Figure 51. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Type (2017-2028)
Figure 52. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Market Size Market Share by Application (2017-2028)
Figure 53. Middle East and Africa Duchenne Muscular Dystrophy Therapeutics Market Size Share by Country (2017-2028)
Figure 54. Turkey Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 55. Saudi Arabia Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 56. UAE Duchenne Muscular Dystrophy Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 57. Bristol-Myers Squibb Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022)
Figure 58. FibroGen (US) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022)
Figure 59. Italfarmaco (Italy) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022)
Figure 60. Marathon Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022)
Figure 61. NS Pharma (US) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022)
Figure 62. PTC Therapeutics (US) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022)
Figure 63. Pfizer Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022)
Figure 64. ReveraGen BioPharma (US) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022)
Figure 65. Santhera Pharmaceuticals (Switzerland) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022)
Figure 66. Sarepta Therapeutics (US) Revenue Growth Rate in Duchenne Muscular Dystrophy Therapeutics Business (2017-2022)
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
